Anticancer therapy with liposomes combined with fluorodeoxyglucose (FDG) using as a tumor detection agent in position emission tomography (PET)

• Project/Area Number: 18591634
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: Hiroshima University
• Principal Investigator: SHIMOSE Shoji Hiroshima University, Hospital, Associate Professor (30304439)
• Co-Investigator(Kenkyū-buntansha): OCHI Mitsuo Hiroshima University, Hospital, Professor (70177244) ; KUBO Tadahiko Hiroshima University, Graduate School of Biomedical Sciences, Assistant Professor (70397959)
• Project Period (FY): 2006 – 2007
• Project Status: Completed (Fiscal Year 2007)
• Budget Amount: ¥3,850,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥450,000); Fiscal Year 2007: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2006: ¥1,900,000 (Direct Cost: ¥1,900,000)
• Keywords: cancer / PET / Liposome

Research Abstract

Positron Emission Tomography (PET) is a diagnostic tool with fluoro-2-deoxyglucose (FDG) ingested by cancer cells have high cell division rate and ingest a lot of glucose. FDG PET is widely used for cancer detection and most commonly applied include lung, breast, colorectal, lymphoma, melanoma, head and neck, sarcoma, cervical, thyroid, and esophageal cancers. If we can use anticancer drags combined with FDG for anticancer therapy, cancer cells will ingest anticancer drag effectively.
Doxorubicin (DOX) FDG-liposomes were prepared with Dipalmitoylphosphatidylcholine (DSPC), Cholesterol, and FDG mixed at the ratio of 5:5:2 and added DOX solution. The liposomes were extruded through polycarbonate membranes of 100-μm-diameter pores to remain in the blood pool and enhance permeability. Cultured MSK cells at 1×10^7 were transplanted into subcutaneous tissue of back of SD rats. Two weeks after transplantation, Doxorubicin, DOX-liposomes, or DOX FDG-liposomes were injected intravenously at a dose of 5mg/kg DOX via jugular vein.
At one week after injections, tumor volumes were 46.5±18.7 cm^3 in untreated (control) group, 13.2±8.7 cm^3 in DOX group, 18.8±7.4 cm^3 in DOX-L group, 6.2±6.0 cm^3 in DOX FDG-L group. Growth of tumors in Doxorubicin and DOX-liposomes group were significantly suppressed as compared with the control group at one week after treatment (P<0.05) and were not suppressed at two or three week. Tumor growth in DOX・FDG-L group was significantly suppressed as compared with the control group at all tested times after treatment (P<0.05). As an index of side effect of DOX, the SD rats were weighted. There were no significant differences in body weights among all groups.
It is suggested that DOX FDG-liposomes can suppress the tumor growth with use of the mechanism of uptake of FDG by tumor cells.